^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The Panel recommends immunotherapy (nivolumab and pembrolizumab) as category 1 preferred options for patients with recurrent or metastatic SCCHN who have progressed on or following platinum-based chemotherapy based on high-quality evidence.
